CN Patent

CN108220295A — PCSK9 iRNA组合物及其使用方法

Assigned to Alnylam Pharmaceuticals Inc · Expires 2018-06-29 · 8y expired

What this patent protects

本发明涉及靶向PCSK9基因的RNAi剂例如双链RNAi剂，和使用这类RNAi剂来抑制PCSK9表达的方法以及治疗患有脂质失调例如高脂血症的受试者的方法。

USPTO Abstract

本发明涉及靶向PCSK9基因的RNAi剂例如双链RNAi剂，和使用这类RNAi剂来抑制PCSK9表达的方法以及治疗患有脂质失调例如高脂血症的受试者的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN108220295A
Jurisdiction
CN
Classification
—
Expires
2018-06-29
Drug substance claim
No
Drug product claim
No
Assignee
Alnylam Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.